Zanubrutinib's new tablet formulation is approved for all five indications, reinforcing its market leadership among BTK inhibitors. The 160 mg tablet simplifies dosing, reducing the daily intake from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback